Year to Date: $938.65M
Company (Symbol)#* Partner (Country) Amt. (M) Triggering Event Details (Date)

Coley Pharmaceuticals Group Inc. (COLY) GlaxoSmithKline plc (UK) $3 Milestone payment For the start of GSK's Phase III trial in non-small-cell lung cancer of an immunotherapeutic cancer vaccine containing Coley's VaxImmune vaccine adjuvant (10/26)
Curis Inc. (CRIS) Genentech Inc. (NYSE:DNA) $3 Milestone payment For the initiation of an expansion cohort in its ongoing Phase I trial of a systemically administered Hedgehog antagonist (10/16)
Genmab A/S (Denmark; CSE:GEN) F. Hoffmann-La Roche Ltd. (Switzerland) ND Milestone payment For Roche's filing of a clinical trial application with British regulatory authorities for a Genmab antibody (10/2)
ImmunoGen Inc. (IMGN) Sanofi-Aventis (France) $1 Milestone payment For the advancement of the TAP compound SAR3419 into Phase I testing (10/17)
Incyte Corp. (INCY) Pfizer Inc. $10 Milestone payment For the filing and acceptance of an investigational new drug application for INCB8696, a CCR2 antagonist for multiple sclerosis (10/11)
Isis Pharmaceuticals Inc. (ISIS) iCo Therapeutics Inc.* (Canada) $1.25 Milestone payment For the initiation of Phase I trials of iCo-007 for the treatment of various eye diseases (10/9)
Isis Pharmaceuticals Inc. (ISIS) Ortho-McNeil Inc. (unit of Johnson & Johnson) $5 Milestone payment For the start of a clinical trial of ISIS 325568, which has demonstrated improved glucose control in animal models of Type II diabetes (10/2)
Ligand Pharmaceuticals Inc. (LGND) Wyeth $0.25 Milestone payment For the submission by Wyeth of a marketing authorization application in Europe for use of bazedoxifene in the prevention and treatment of osteoporosis (10/15)
NPS Pharmaceuticals Inc. (NPSP) Kirin Pharma (Japan) ND Milestone payment For the approval in Japan of cinacalcet hydrochloride to treat secondary hyper-parathyroidism (10/25)
Seattle Genetics Inc. (SGEN) MedImmune Inc. (unit of AstraZeneca plc; UK; LSE:MDI) $1.5 Milestone payment For the exercise of an option to obtain an exclusive license to a second antigen target under their existing antibody-drug conjugate collaboration (10/31)
Targeted Genetics Corp. (TGEN) Amsterdam Molecular Therapeutics BV (the Netherlands) ND Milestone payment As part of a licensing agreement that provides AMT with non-exclusive rights to patents covering Adeno-Associated Virus type 1 (10/4)
Zealand Pharma AS* (Denmark) Wyeth Pharmaceuticals ND Milestone payment For the advancement of the first orally available gap junction modifier ZP1609 into Phase I trials in the U.S. (10/10)


# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Private company. Currency conversions are based on exchange rates at the time of the deal. ND = Not disclosed. OTC BB = Over-the-Counter Bulletin Board.